# Hims rides the weight-loss boom, FDA is the risk

By @Kaizen_Investor on X · https://f.xyz/t/417b0ebd-2382-46ca-92db-d7e6d7859c0f

> Hims & Hers will profit from the weight-loss drug boom through subscriber growth, but an FDA ruling on compounded drugs could break the story.

**Result:** If held over the last 3 months (Aug 11, 2026 – Nov 10, 2026): −2.9%. Over the same days: S&P 500 −4.1%, BTC +15.9%.

## What it holds

- **The Hims bet** (55%, −13.7% over 3 months): HIMS (Hims & Hers Health) −13.7%
- **The drug maker** (30%, +12.9% over 3 months): LLY (Eli Lilly) +12.9%
- **Cash** (15%)

## The plan behind it

The main bet is Hims, because it is the company he named and it wins if more people subscribe and revenue keeps growing. Eli Lilly is added because it makes the weight-loss drugs behind the boom, and he called the new Hims link with Lilly a good sign. If Hims sells more of Lilly's real drugs, both stocks can win together. I kept some cash because he said the FDA ruling on copied (compounded) drugs is a yes-or-no risk that could hit Hims hard. The cash cushions a bad surprise.

> $HIMS will report earnings after the bell today. It is my favorite opportunity outside the AI trade. They're well positioned to profit from the GLP-1 boom. The recent cooperation with $LLY is another step in the right direction.
> 
> Analysts are expecting another record revenue quarter. Hims is well on its way to a first $1B quarter; this quarter, analysts expect $900M in revenue. The EPS is expected to land at $0.06.
> 
> HIMS is still down 60% from its highs 1.5 years ago. I had doubts about management, but since then, I think they have fundamentally strengthened the company. They have several strong growth pillars to grow subscribers, which, for me, is the most important metric.
> 
> Tonight will also be important for other metrics.
> 
> Compounded Drug Regulations: My long-term thesis relies heavily on selling compounded GLP-1 weight-loss drugs, which has drawn intense FDA and DOJ scrutiny. If the FDA officially declares the national semaglutide shortage over, Hims could face immediate restrictions on selling these high-growth products, making regulatory commentary the most critical binary risk.
> 
> Margin Compression: Historically, Hims boasted ~80% gross margins on its legacy treatments (like hair loss and ED). However, their shift toward weight-loss drugs and international expansion has compressed gross margins down to the mid-60s. I want to know if this deterioration is stabilizing or if the new product mix will permanently lower their profitability profile.
> 
> Subscriber Retention & Disputes: Visa recently penalized Hims and placed it in a monitoring program due to a spike in credit card chargebacks, heavily concentrated in its weight-loss subscriptions. Combined with an ongoing FTC lawsuit over difficult cancellation practices, it is important to see whether users are actually retaining, or whether the company is burning through capital on low-quality subscribers.
> 
> Free Cash Flow Timeline: Despite massive top-line growth, operating cash flow turned negative in Q2 as receivabl
> — @Kaizen_Investor on X: https://x.com/Kaizen_Investor/status/2119734026177032515

**What would prove it wrong:** The FDA ends the semaglutide shortage and forces Hims to stop selling compounded drugs, or subscribers start leaving fast.

## FAQ

### How do I bet that Hims & Hers will profit from the weight-loss drug boom through subscriber growth, but an FDA ruling on compounded drugs could break the story?

This tested idea holds HIMS (Hims & Hers Health) and LLY (Eli Lilly), with 15% in cash. Make a copy to run it on practice money first, at real prices.

### What would prove it wrong?

The FDA ends the semaglutide shortage and forces Hims to stop selling compounded drugs, or subscribers start leaving fast.

### Can I make one from my own idea?

Yes. Write what you believe in plain words at https://f.xyz/create. fxyz asks a couple of questions, builds the portfolio and shows how it would have done over the last 3 months.

### Can I turn a post on X into a theory?

Yes. Reply to the post and tag @fxyzai. It tests the view in the post and replies with the 3-month result and a link.

### What can it trade?

Stocks (Tesla, Apple, Nvidia), crypto (Bitcoin, Ethereum, Solana), pre-IPO companies (OpenAI, Anthropic), indices (Nasdaq 100, S&P 500), commodities (gold, silver, oil, copper) and currencies (EUR/USD, USD/JPY). One theory can mix them, and bet for or against any of them.

### How does it react to news?

On each check it reads the last two days of news on its biggest holdings and says whether the idea still holds. It can make one small change at a time: trim or drop one holding by up to 5 points. On autopilot the change waits 10 minutes so the owner can skip it; otherwise it asks first.

### How do I run it with real money?

For real money, tap Make it mine, open your copy and choose Use real money, with an exchange connected: Hyperliquid, Lighter, Lighter (Robinhood), Backpack, Pacifica or Binance. The money stays in your own account there. fxyz can place trades, but it can never withdraw.

### Can the AI get it wrong?

Yes. fxyz's AI turns the idea into holdings, and it can get that wrong: add a coin or stock that doesn't fit, or miss one that does. Check the holdings before you put money in. In your own copy, ask its chat to add or drop any of them.

### What do the 3-month numbers mean?

What $100 would have done holding this mix over the last 3 months, at real prices. It is a what-if, not a record: past or simulated results are no promise of future ones, and nothing here is investment advice.

Test your own idea: https://f.xyz/test
